<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
		>
<channel>
	<title>Comments on: Q Therapeutics&#8217; and Invitrogen&#8217;s Symbiotic Relationship</title>
	<atom:link href="http://regeneration-station.com/2008/02/25/q-therapeutics-and-invitrogens-symbiotic-relationship/feed/" rel="self" type="application/rss+xml" />
	<link>http://regeneration-station.com/2008/02/25/q-therapeutics-and-invitrogens-symbiotic-relationship/</link>
	<description>Stem cells, biomaterials, engineered tissues, and other cell-based technologies.  The guts of the Regenerative Medine industry.</description>
	<lastBuildDate>Wed, 06 May 2009 18:40:22 +0000</lastBuildDate>
	<generator>http://wordpress.com/</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: jrowley</title>
		<link>http://regeneration-station.com/2008/02/25/q-therapeutics-and-invitrogens-symbiotic-relationship/#comment-32</link>
		<dc:creator>jrowley</dc:creator>
		<pubDate>Mon, 25 Feb 2008 23:31:38 +0000</pubDate>
		<guid isPermaLink="false">http://regenerationstation.wordpress.com/?p=97#comment-32</guid>
		<description>To answer your question: I think all life science companies have been watching cell therapy for a long time. They are all trying to figure out how to profit from the field.  Some, like Invitrogen, will profit by selling tools (kits and QC assays, GMP-grade culture media and reagents, equipment) to the therapeutic companies, and others, like Celgene, BD or JNJ, will actually be looking to enter the therapeutic arena (much riskier, but more potential reward).  I hope that helps - thanks for the comments!</description>
		<content:encoded><![CDATA[<p>To answer your question: I think all life science companies have been watching cell therapy for a long time. They are all trying to figure out how to profit from the field.  Some, like Invitrogen, will profit by selling tools (kits and QC assays, GMP-grade culture media and reagents, equipment) to the therapeutic companies, and others, like Celgene, BD or JNJ, will actually be looking to enter the therapeutic arena (much riskier, but more potential reward).  I hope that helps &#8211; thanks for the comments!</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: hemato</title>
		<link>http://regeneration-station.com/2008/02/25/q-therapeutics-and-invitrogens-symbiotic-relationship/#comment-31</link>
		<dc:creator>hemato</dc:creator>
		<pubDate>Mon, 25 Feb 2008 06:23:21 +0000</pubDate>
		<guid isPermaLink="false">http://regenerationstation.wordpress.com/?p=97#comment-31</guid>
		<description>Very good analytics! 
it is pleasure to read professional opinion.
I just wondering how Invitrogen became highly interested in cell therapy and how they are going to fit in this field.
But I like their steps so far and I think they are really smart guys, including Dr. Rao</description>
		<content:encoded><![CDATA[<p>Very good analytics!<br />
it is pleasure to read professional opinion.<br />
I just wondering how Invitrogen became highly interested in cell therapy and how they are going to fit in this field.<br />
But I like their steps so far and I think they are really smart guys, including Dr. Rao</p>
]]></content:encoded>
	</item>
</channel>
</rss>
